Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 11 (November)

1. Elevation of thyroid cancer risk among cutaneous melanoma survivors.
   Int J Cancer, 118(1): 185-8. [Abstract] [Full-text]
2. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
   Proc Natl Acad Sci U S A, 102(44): 16013-8. [Abstract] [Full-text]
3. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
   Cancer Res, 65(21): 10068-78. [Abstract] [Full-text]
4. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
   Cancer Res, 65(21): 10059-67. [Abstract] [Full-text]
5. Focal adhesion kinase promotes the aggressive melanoma phenotype.
   Cancer Res, 65(21): 9851-60. [Abstract] [Full-text]
6. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers.
   Clin Chim Acta, 362(1): 85-93. [Abstract] [Full-text]
7. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3.
   Br J Cancer, 93(10): 1191-6. [Abstract] [Full-text]
8. Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk / Bik.
   Oncogene, 24(49): 7369-80. [Abstract] [Full-text]
9. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
   Pigment Cell Res, 18(6): 411-6. [Abstract] [Full-text]
10. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.
    Int J Cancer, 118(2): 472-6. [Abstract] [Full-text]
11. Concentration-dependent effects of N1, N11-diethylnorspermine on melanoma cell proliferation.
    Int J Cancer, 118(2): 509-12. [Abstract] [Full-text]
12. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.
    Int J Cancer, 118(2): 373-80. [Abstract] [Full-text]
13. Distinct sets of genetic alterations in melanoma.
    N Engl J Med, 353(20): 2135-47. [Abstract] [Full-text]
14. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo.
    Oncogene, 24(51): 7624-9. [Abstract] [Full-text]
15. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Clin Exp Immunol, 142(3): 555-68. [Abstract] [Full-text]
16. Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ.
    Arch Dermatol, 141(11): 1413-8. [Abstract] [Full-text]
17. The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma.
    Arch Dermatol, 141(11): 1388-96. [Abstract] [Full-text]
18. Characterization of ocular and metastatic uveal melanoma in an animal model.
    Invest Ophthalmol Vis Sci, 46(12): 4376-82. [Abstract] [Full-text]
19. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
    Invest Ophthalmol Vis Sci, 46(12): 4372-5. [Abstract] [Full-text]
20. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
    Invest Ophthalmol Vis Sci, 46(12): 4365-71. [Abstract] [Full-text]
21. Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism.
    Br J Cancer, 93(11): 1244-9. [Abstract] [Full-text]
22. Is incisional biopsy of melanoma harmful?
    Am J Surg, 190(6): 913-7. [Abstract] [Full-text]
23. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
    Cancer Immunol Immunother, 55(2): 178-84. [Abstract] [Full-text]
24. ICAM-1 polymorphisms and development of cutaneous malignant melanoma.
    Int J Immunogenet, 32(6): 367-73. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.